Inhaled insulin - The breakthrough in the treatment of diabetes?;Insulina wziewna - Kolejny milowy krok w leczeniu cukrzycy?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 9, 2007, Pages 415-419

  Szymborska Kajanek, Aleksandra ^a   Wrobel, Marta ^a   Grzeszczak, Wladysław ^a   Strojek, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Inhaled insulin; Type 1 diabetes; Type 2 diabetes

Indexed keywords

INSULIN;

CONFUSION; DIABETES MELLITUS; DISEASE COURSE; FEAR; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; WEIGHT GAIN;

EID: 36549072907     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053.
2. Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. Diabetes Care. 2004; 27 (Suppl 1): S5-S10.
3. Genuth S. Insulin use in NIDDM. Diabetes Care. 1990; 13: 1240-1264.
4. The Diabetes Control and Complications Trial Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 14: 977-986.
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
6. Sieradzki J, Grzeszczak W, Karnafel W, et al. Badanie Pol Diab. Czȩść I. Analiza leczenia cukrzycy w Polsce. Diabet Prakt. 2006; 3: 8-15.
7. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin treated diabetes. Diabetes Res Clin Pract. 1999; 46: 239-246.
8. Exubera. Treatment of type 1 and type 2 diabetes. Drugs of the Future. 2004; 29: 1206-1210.
9. Harsch IA. Inhaled insulins: their potential in the treatment of diabetes mellitus. Treat Endocrinol. 2005; 4: 131-138.
10. Heubner W, De Jongh S, Laquer E. Über inhalation von insulin. Klin Wochenschr. 1924.
11. Gansslen M. Über inhalatiuon von insulin. Klin Wochenschr. 1925: 4: 71.
12. Byron PR: Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986: 75: 433-438.
13. Cernea S, Kidron M, Wohlgelernter J, et al. Comparision of pharmacokinetic and pharmacodynamic properties of single-dose oral spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther. 2004; 26: 2084-2091.
14. Cherrington AD, Neal DW, Edgerton DS, et al. Inhalation of insulin in dogs. Assessment of insulin levels and comparison to subcutaneous injection. Diabetes. 2004; 53: 877-881.
15. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005; 28: 1077-1082.
16. Quattrin T, Belanger A, Bohannon NJV, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care. 2004; 27: 2622-2627.
17. Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes. A randomized controlled trial. Diabetes Care. 2001; 24: 1556-1559.
18. De Fronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care. 2005; 28: 1922-1928.
19. Simonson DC, Turner RR, Hades JE, et al. Improving quality of life in type 2 diabetes when Exubera is added after failure on metformin. A multicenter, international trial. 40th Annu Sci Sess Am Diabetes Assoc. 2004; abstr. 865.
20. Testa MA, Turner RR, Hades JF, et al. Satisfaction and quality of life with sulfonylurea plus either metformin or Exubera. An international randomized phase 3 trail. 64th Ann Sci Sess Am Diabetes Assoc. 2004; abstr. 487-P.
21. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care. 2004; 27: 2356-2362.
22. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med. 2005; 143: 549-558.
23. Weiss SR, Cheng SL, Kourides IA, et al. Inhaled insulin provides improved glycemic control in patients with Type 2 diabetes mellitus inadequately controlled with oral agents: a randomizes controlled trial. Arch Intern Med. 2003; 163: 2277-2282.
24. Kokoszka A, Sieradzki J. Poczucie wpływu na przebieg choroby a sposób leczenia cukrzycy. Diabet Prakt. 2005; 6: 1-5.
25. FreemantJe N, Blond L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy In patients with type diabetes. Diabetes Care. 2005; 28: 427-428.
26. Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparision between an inahaled insulin regime and a subcutaneous insulin regimen. Clin Ther. 2002; 24: 552-564.
27. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 854-865.
28. Belanger A. Efficacy and safety of inhaled insulin (Exubera) compared to subcutaneous insulin therapy in patients with type 2 diabetes: results of 6-month, randomized, comparative trial. Exubera phase III Study Group. Diabetologia. 2002; 45 (Suppl 1): A260-A261.
29. Heine T, Bott S, Tusek C, et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. Diabetes Care. 2005; 28: 2161-2169.
30. Fineberg SE, Schatz D, Krasner A. Results of insulin antibody monitoring during phase II and III clinical studies of inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetologia. 2002; 45 (Suppl 2): A17.
31. Barnett AH. Efficacy and one-year pulmonary safety of inhaled insulin (Exubera) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy. Diabetes. 2004; 53: A107.
32. De Fronzo RA, for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: results of a 3-month, randomized, comparative trial. Diabetes. 2003; 52: A38.
33. Mather LE, Clauson P, Uy C. Pharmacokinetics and pharmacodynamics of pulmonary insulin using the AERx insulin diabetes management system during and after an upper respiratory tract infection. An open labeled crossover study in healthy volunteers. EASD 2002; 32: A261.
34. Henry RR, Mudaliar SR, Howland WC, et al. Inhaled insulin using the AER Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care. 2003; 26: 764-769.
35. Sha S, Becker R, Willavize S, et al. The effect of smoking cessation on the absorption of inhaled insulin (Exubera). Diabetes. 2002; 51: A133.
36. Dreyer M. Efficacy and two-year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral therapy. Diabetologia. 2004; 47: A44.
37. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001; 357: 331-335.
38. Gomez-Perez FJ, Rull JA. Insulin therapy: current alternatives. Archives of Medical Research. 2005; 36: 258-272.